Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

MRSN Relative to the S&P 500

MRSN Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Mersana Therapeutics, Inc. (NASD:MRSN) seasonal charts above shows that a Buy Date of September 25 and a Sell Date of December 17 has resulted in a geometric average return of 21.23% above the benchmark rate of the S&P 500 Total Return Index over the past 8 years. This seasonal timeframe has shown positive results compared to the benchmark in 6 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 8 years by an average of 58.59% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 8 years of data is available for shares of MRSN, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

To download MRSN seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: MRSN